Celgene’s $9B Buyout of Juno to Boost Company’s Immuno-Oncology Portfolio
News
Celgene says it will buy Juno Therapeutics for $9 billion in a deal that could make Celgene a world leader in immuno-oncology treatments. Specifically, the Jan. 22 deal gives the New Jersey-based ... Read more